Document 0819
 DOCN  M9470819
 TI    Comparative efficacy and safety of bifonazole 1% cream and the
       corresponding base preparation in the treatment of seborrhoeic
       dermatitis.
 DT    9409
 AU    Zienicke H; Korting HC; Braun-Falco O; Effendy I; Hagedorn M;
       Kuchmeister B; Meisel C; Dermatologische Klinik und Poliklinik,;
       Ludwig-Maximilians-Universitat, Munich, Germany.
 SO    Mycoses. 1993 Sep-Oct;36(9-10):325-31. Unique Identifier : AIDSLINE
       MED/94285960
 AB    Seborrhoeic dermatitis is a common entity that conventionally is
       difficult to treat. Recently, topical ketoconazole has been proven
       successful. To determine if other azoles, and in particular the more
       modern ones, are also helpful in this condition, a double-blind
       multicentre randomized controlled trial was performed in patients
       suffering from seborrhoeic dermatitis involving individuals 16 years and
       older without human immunodeficiency virus (HIV) infection. One hundred
       patients were enrolled and treated according to a random plan with
       either bifonazole 1% cream or the corresponding vehicle once daily for 4
       weeks. All patients were evaluated at the beginning of the study, as
       well as after 2 and 4 weeks, i.e. the treatment period proper, and after
       6 weeks of follow-up. Clinical evaluation was based on scores of 0-3 for
       the following parameters: erythema, papules, infiltration, scaling,
       itch. In addition, mycological evaluation was performed using adequate
       contact plates for quantitative determination of Malassezia furfur. In
       the end, 92 patients were at least partially evaluable. In general, the
       verum preparation tended to be more efficacious, e.g. the score for
       erythema amounted to 0.75 after 4 weeks as compared with 0.88 in the
       control group, the baseline values being 2.18 and 2.04 respectively.
       With itch, the corresponding figures were 0.17 and 0.33 as compared with
       1.42 and 1.38 before treatment. While in statistical terms there was
       significant difference in these parameters, such a difference was
       demonstrated by clinical judgement at follow-up.(ABSTRACT TRUNCATED AT
       250 WORDS)
 DE    Administration, Topical  Adult  Antifungal Agents/ADMINISTRATION &
       DOSAGE/ADVERSE EFFECTS/  *THERAPEUTIC USE  Dermatitis, Seborrheic/*DRUG
       THERAPY/PATHOLOGY  Dosage Forms  Double-Blind Method  Female  Human
       Imidazoles/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC  USE
       Male  Middle Age  CLINICAL TRIAL  JOURNAL ARTICLE  MULTICENTER STUDY

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).